Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Employees - 37, CEO - Mr. Marvin L. White, Sector - Healthcare, Country - US, Market Cap - 2.90M

Altman ZScore(max is 10): -26.99, Piotroski Score(max is 10): 2, Working Capital: $4452000, Total Assets: $15591000, Retained Earnings: $-247577000, EBIT: -24602000, Total Liabilities: $10836000, Revenue: $0

- Current Price $1.99 - Analyst Target Price $21.00